Last reviewed · How we verify
Continuous Denosumab
Continuous Denosumab, marketed by National Taiwan University Hospital, holds a niche position in the pharmaceutical market with its unique mechanism of action. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of exclusivity and protection against generic competition. The primary risk is the lack of detailed revenue data and key trial results, which may limit the drug's visibility and market appeal.
At a glance
| Generic name | Continuous Denosumab |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture (NA)
- Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (PHASE4)
- Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (PHASE2)
- PRevEnting FracturEs in REnal Disease - 1 (PHASE4)
- The Optimal Long Term Treatment Strategy of Anti-resorptive Medications (PHASE4)
- Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone (PHASE4)
- Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous Denosumab CI brief — competitive landscape report
- Continuous Denosumab updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI